Leticia Irene Llarrull

Dr. Leticia Irene Llarrull

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LOLisandro H. Otero
Lisandro H. Otero
ARAlzoray Rojas-Altuve
Alzoray Rojas-Altuve
LLLeticia Irene Llarrull
Leticia Irene Llarrull
César Carrasco-LópezCésar Carrasco-López
César Carrasco-López
MKMalika Kumarasiri
Malika Kumarasiri
JHJuan Hermoso
Juan Hermoso
The expression of penicillin binding protein 2a (PBP2a) is the basis for the broad clinical resistance to the β-lactam antibiotics by methicillin-resistant Staphylococcus aureus (MRSA). The high-molecular mass penicillin binding proteins of bacteria catalyze in separate domains the transglycosylase and transpeptidase activities required for the biosynthesis of the peptidoglycan polymer that comprises the bacterial cell wall. In bacteria susceptible to β-lactam antibiotics, the transpeptidase activity of their penicillin binding proteins (PBPs) is lost as a result of irreversible acylation of an active site serine by the β-lactam antibiotics. In contrast, the PBP2a of MRSA is resistant to β-lactam acylation and successfully catalyzes the dd-transpeptidation reaction necessary to complete the cell wall. The inability to contain MRSA infection with β-lactam antibiotics is a continuing public health concern. We report herein the identification of an allosteric binding domain—a remarkable 60 Å distant from the dd-transpeptidase active site—discovered by crystallographic analysis of a soluble construct of PBP2a. When this allosteric site is occupied, a multiresidue conformational change culminates in the opening of the active site to permit substrate entry. This same crystallographic analysis also reveals the identity of three allosteric ligands: muramic acid (a saccharide component of the peptidoglycan), the cell wall peptidoglycan, and ceftaroline, a recently approved anti-MRSA β-lactam antibiotic. The ability of an anti-MRSA β-lactam antibiotic to stimulate allosteric opening of the active site, thus predisposing PBP2a to inactivation by a second β-lactam molecule, opens an unprecedented realm for β-lactam antibiotic structure-based design.

1 October 2010 in Current Opinion in Microbiology
Verified
Journal Article
Closed access
LLLeticia Irene Llarrull
Leticia Irene Llarrull
STSebastian A Testero
Sebastian A Testero
JFJed F Fisher
Jed F Fisher
SMShahriar Mobashery
Shahriar Mobashery

21 February 2014 in Journal of the American Chemical Society
Verified
Journal Article
Open access
POPeter I. O’dAniel
Peter I. O’dAniel
ZPZhihong Peng
Zhihong Peng
HPHualiang Pi
Hualiang Pi
STSebastian A. Testero
Sebastian A. Testero
DDDerong Ding
Derong Ding
MCMayland Chang
Mayland Chang
Infections caused by hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA) are a serious global public-health concern, as MRSA has become broadly resistant to many classes of antibiotics. We disclose herein the discovery of a new class of non-β-lactam antibiotics, the oxadiazoles, which inhibit penicillin-binding protein 2a (PBP2a) of MRSA. The oxadiazoles show bactericidal activity against vancomycin- and linezolid-resistant MRSA and other Gram-positive bacterial strains, in vivo efficacy in a mouse model of infection, and have 100% oral bioavailability.

14 June 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PHPhilip Hinchliffe
Philip Hinchliffe
MGMariano M. González
Mariano M. González
MMMaria Mojica
Maria Mojica
JGJavier M. González
Javier M. González
VCValerie Castillo
Valerie Castillo
JSJames Spencer
James Spencer
Metallo-β-lactamases (MBLs) hydrolyze almost all β-lactam antibiotics and are unaffected by clinically available β-lactamase inhibitors (βLIs). Active-site architecture divides MBLs into three classes (B1, B2, and B3), complicating development of βLIs effective against all enzymes. Bisthiazolidines (BTZs) are carboxylate-containing, bicyclic compounds, considered as penicillin analogs with an additional free thiol. Here, we show both l- and d-BTZ enantiomers are micromolar competitive βLIs of all MBL classes in vitro, with Kis of 6–15 µM or 36–84 µM for subclass B1 MBLs (IMP-1 and BcII, respectively), and 10–12 µM for the B3 enzyme L1. Against the B2 MBL Sfh-I, the l-BTZ enantiomers exhibit 100-fold lower Kis (0.26–0.36 µM) than d-BTZs (26–29 µM). Importantly, cell-based time-kill assays show BTZs restore β-lactam susceptibility of Escherichia coli-producing MBLs (IMP-1, Sfh-1, BcII, and GOB-18) and, significantly, an extensively drug-resistant Stenotrophomonas maltophilia clinical isolate expressing L1. BTZs therefore inhibit the full range of MBLs and potentiate β-lactam activity against producer pathogens. X-ray crystal structures reveal insights into diverse BTZ binding modes, varying with orientation of the carboxylate and thiol moieties. BTZs bind the di-zinc centers of B1 (IMP-1; BcII) and B3 (L1) MBLs via the free thiol, but orient differently depending upon stereochemistry. In contrast, the l-BTZ carboxylate dominates interactions with the monozinc B2 MBL Sfh-I, with the thiol uninvolved. d-BTZ complexes most closely resemble β-lactam binding to B1 MBLs, but feature an unprecedented disruption of the D120–zinc interaction. Cross-class MBL inhibition therefore arises from the unexpected versatility of BTZ binding.

20 August 2015 in FEBS Letters
Verified
Journal Article
Closed access
MMMaria-Rocio Meini
Maria-Rocio Meini
LLLeticia Irene Llarrull
Leticia Irene Llarrull
AVAlejandro Vila
Alejandro Vila

1 October 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
LLLeticia Irene Llarrull
Leticia Irene Llarrull
JFJed F. Fisher
Jed F. Fisher
SMShahriar Mobashery
Shahriar Mobashery